Bpifrance

MSInsight is a bioinformatics startup that specializes in developing diagnostic and treatment response prediction solutions for cancers with Microsatellite Instability (MSI). The company's core offering revolves around identifying and analyzing diagnostic and prognostic biomarkers of treatment response in MSI tumors. By leveraging next-generation sequencing data, MSInsight's platform provides actionable insights on MSI status, a critical biomarker for cancer treatment, enabling healthcare professionals to make informed decisions about patient care, particularly in relation to immunotherapy options, and ultimately improve patient outcomes.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, aimed at treating disorders related to spinal cord injuries. The company utilizes HSV-1-based vectors, leveraging the natural characteristics of the Herpes Simplex Virus 1 to establish lifelong latency in peripheral neurons. This innovative approach allows for targeted and sustained expression of therapeutic genes, providing a potential cure for severe, chronic, and localized conditions, such as neurogenic bladder disorders resulting from spinal cord injuries. By focusing on this advanced gene therapy technique, EG 427 seeks to improve treatment outcomes for patients suffering from these debilitating conditions.

Ochy is a mobile application that leverages video technology and artificial intelligence to deliver lab-quality analysis of running techniques directly to users' smartphones. The platform is designed to help runners assess their biomechanics, identify weaknesses, and receive tailored exercise plans aimed at enhancing performance and preventing injuries. By analyzing users' movements, Ochy provides insights that can support athletes, coaches, and medical professionals alike. Coaches can utilize the app to better understand their athletes and optimize training programs, while runners without access to coaching can independently evaluate their technique. Additionally, medical professionals can use the application's analysis to assess patient techniques and guide rehabilitation efforts effectively.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Biolevate is an AI-driven company focused on enhancing healthcare research and patient care. It offers IT consulting services, employing advanced AI algorithms to streamline research workflows. The company's platform automates tasks such as document generation and literature monitoring, intelligently filtering vast datasets to provide relevant, actionable scientific information. It offers customizable search options and insightful data visualizations, empowering clients to make informed decisions and accelerate scientific breakthroughs, ultimately improving patient care.

Primaa is a MedTech company that specializes in developing an AI-based platform for the automated and accurate diagnosis of cancer. The company's innovative software utilizes image analysis and deep learning techniques to improve the detection of key cancer biomarkers. By digitizing histological slides and compiling images into a comprehensive database, Primaa's technology allows medical professionals to efficiently identify tissue damage and conduct a growing number of diagnoses with a high degree of reliability. This approach not only enhances diagnostic accuracy but also supports personalized treatment plans for patients.

Fudzs is a pioneer in the sustainable bioeconomy, specializing in the development of eco-friendly cell bioproduction processes utilizing advanced bioreactor technology. The company focuses on the mass production of cells through innovative biomaterial engineering combined with cellular science, which enables cost-effective solutions for various industries. Fudzs aims to revolutionize the cultivated meat sector by creating affordable and high-quality meat alternatives, as well as enhancing cell therapies. Its proprietary approach to biomaterials is optimized for cell growth, significantly increasing cell amplification and density in bioreactors, thereby unlocking new market opportunities and promoting a more sustainable future in food production and healthcare.

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.

Enalees is a biotechnology company focused on developing molecular diagnostic tests specifically for pets. The company has created a platform that enables veterinarians to quickly identify microbes responsible for infectious diseases in leisure animals, such as horses. By providing DNA tests that can detect infections, Enalees facilitates timely diagnosis in veterinary clinics, allowing for more effective treatment of animal pathologies. This innovative approach aims to enhance the veterinary diagnostic process and improve animal health outcomes.

Archeon is focused on creating innovative solutions for the monitoring, diagnosis, and treatment of critically ill patients in prehospital care. The company develops artificial intelligence-based technologies aimed at enhancing ventilation quality in emergency medical services. Its products are designed to be practical, user-friendly, and intuitive for emergency caregivers, providing real-time feedback on the quality of ventilation administered to patients. This approach aims to improve patient outcomes and support medical professionals in high-pressure situations.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Ray Studios is a Tattoo removal studio that employs hydraulic acoustic wave technology in its "Le Ray Spark" Tattoo removal treatment device.

Starkage Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients suffering from various health conditions. The company is developing a platform that targets the depletion of senescent cells, which are linked to age-related diseases, through a combination of immunotherapy and cancer treatment approaches. Starkage Therapeutics aims to address unmet medical needs in areas such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibrosis. Through its innovative research and therapeutic strategies, the company seeks to enhance patient health and treatment outcomes.

Biodol Therapeutics SAS, founded in 2015 and located in Clapiers, France, focuses on developing innovative treatments for chronic pain. The company has identified the receptor tyrosine kinase FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain. Through its proprietary approach, Biodol Therapeutics develops extracellular inhibitors of the FLT3 receptor, which aim to inhibit ligand binding and thereby alleviate conditions such as allodynia, pain hypersensitivity, and spontaneous pain without disrupting normal nervous system function. Additionally, research partnerships have indicated that inhibiting FLT3 may enhance the efficacy of opioids, potentially reducing their associated risks, including addiction. This innovative work positions Biodol Therapeutics as a significant player in addressing chronic pain and contributing to solutions for the opioid crisis.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Klineo operates a digital platform that simplifies and enhances access to clinical trials for oncology patients and healthcare professionals. The platform offers two user interfaces, one for patients and one for doctors, enabling them to search for and connect with relevant clinical trials, particularly for breast, skin, and lymphoma conditions.

Pixacare is a company that develops a medical imaging application aimed at enhancing wound care management for healthcare professionals. This secure and collaborative platform automates medical photo management and centralizes essential data for monitoring wounds, making it user-friendly on both mobile and desktop devices. The application is a Class I CE-marked digital medical device that integrates seamlessly with existing healthcare infrastructures, including Patient Administration Systems and Electronic Health Records, ensuring interoperability. By transforming any smartphone camera into a secure documentation tool, Pixacare enables home-care staff, surgeons, and dermatologists to monitor and anticipate complications in chronic and post-surgery wounds. This innovation allows healthcare professionals to optimize their activities and save time in visual specialties while ensuring data security through hosting on certified Health Data Hosting servers.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Pixee Medical is a medical technology company based in Chavanod, France, founded in 2017. The company specializes in the manufacturing of computer-assisted surgical solutions that utilize advanced computer vision and artificial intelligence technologies. Pixee Medical produces medical equipment designed to control the positioning of implants during orthopedic surgeries. Its innovative tracking tools enable precise three-dimensional localization of surgical objects, allowing healthcare professionals to perform procedures with millimeter accuracy. By focusing on affordability, Pixee Medical aims to provide effective surgical navigation solutions that address the challenges of the current healthcare environment.

AQEMIA is a pharmatech company focused on drug discovery, utilizing a platform that integrates machine learning with quantum-inspired physics. This innovative approach allows for the efficient identification of new drug candidates aimed at specific therapeutic targets. By employing advanced algorithms, AQEMIA's platform is capable of predicting the interactions and affinities between potential drug molecules and their targets. This methodology not only accelerates the drug discovery process but also contributes to a growing pipeline of viable drug candidates for various medical applications.

Ochy is a mobile application that leverages video technology and artificial intelligence to deliver lab-quality analysis of running techniques directly to users' smartphones. The platform is designed to help runners assess their biomechanics, identify weaknesses, and receive tailored exercise plans aimed at enhancing performance and preventing injuries. By analyzing users' movements, Ochy provides insights that can support athletes, coaches, and medical professionals alike. Coaches can utilize the app to better understand their athletes and optimize training programs, while runners without access to coaching can independently evaluate their technique. Additionally, medical professionals can use the application's analysis to assess patient techniques and guide rehabilitation efforts effectively.

Huvy specializes in developing a skin cancer screening application that utilizes artificial intelligence to enhance dermatological treatment pathways. The application aims to identify cancer risks and provide essential medical information in real-time. By facilitating dermatological screening, Huvy's technology enables access to initial diagnostic orientation for populations in areas with limited medical resources. This approach allows for timely care and intervention when there is a suspicion of skin cancer, ultimately improving health outcomes for underserved communities.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

BariaTek is a provider of innovative solutions in the field of bariatric surgery. The company focuses on offering minimally invasive treatments that mimic the effects of traditional surgery through the use of advanced endoscopic techniques. By utilizing trans-oral access and implantable devices, BariaTek aims to provide patients with a painless alternative to conventional bariatric procedures. This approach not only enhances patient comfort but also seeks to improve health outcomes by facilitating effective weight loss and disease management.

EverImmune is focused on developing innovative biotherapeutic products aimed at treating cancer patients through microbiome oncology. The company specializes in creating live biotherapeutic products (LBP) that serve as oral adjuvants to enhance anticancer immunotherapies. By leveraging technology to safely boost the immune system and restore sensitivity to immunotherapies, EverImmune seeks to improve the effectiveness of cancer treatments, particularly in cases of primary resistance. The firm plans to conduct well-designed clinical trials to test its lead product, Oncobax®, as part of its commitment to advancing cancer care.

Resolve Stroke, headquartered in Paris, is a HealthTech company dedicated to revolutionizing medical imaging. It specializes in enhancing ultrasound technology to extract more detailed information, enabling advanced diagnostics, particularly in neurology. The company's innovative software engines improve ultrasound contrast, resolution, and penetration depth, allowing for the visualization of micro-vessels through the human skull in 3D. With a global focus, Resolve Stroke aims to accelerate treatments for over 1 billion people affected by brain diseases. To date, it has secured €3 million in pre-seed funding to pioneer software-based ultrasound innovation.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

BioMAdvanced Diagnostics focuses on developing molecular diagnostic and biomarker tests that enhance patient care by integrating seamlessly into existing diagnostic and treatment protocols. The company's tests are designed to be user-friendly for healthcare personnel and economically accessible. By providing predictive scores and identifying biomarkers, these tests assist clinicians in evaluating and diagnosing the risk of transplant rejection, thereby enabling more effective and individualized treatment strategies. This approach aims to significantly improve patient outcomes by equipping physicians with advanced tools to monitor and manage their patients' immune responses.

Microoled is a French company specializing in the development and manufacturing of microdisplays for mobile near-to-eye viewing devices. Established in 2007 and headquartered in Grenoble, the company focuses on creating AMOLED displays and optical modules that cater to various sectors, including consumer electronics, medical applications, and security. Microoled's product range encompasses video glasses, head-mounted sports devices, and camera viewfinders, among other professional equipment. By addressing customer needs and anticipating market demands, Microoled aims to enhance user experiences across diverse applications.

GenSensor is a biotechnology company that specializes in developing and implementing a genomic-based, in-line bioproduction monitoring system. This system combines a robotic device with advanced analytics software to monitor, characterize, and optimize the production of advanced therapy medicinal products (ATMPs) and vaccines. By providing real-time insights into the bioproduction process, GenSensor helps healthcare companies maximize the use of innovative drugs, improve production efficiency, and ultimately reduce manufacturing costs, thereby benefiting patients.

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

Gleamer is a company specializing in artificial intelligence-based solutions for radiology, focusing on enhancing diagnostic accuracy for medical imaging. By integrating its AI companions into the existing reading environments of radiologists, Gleamer provides an automated second reading that aids in the detection of bone abnormalities, lesions, and other critical details in X-ray images. This technology not only improves efficiency but also helps ensure that all patients receive accurate diagnoses. Currently, Gleamer's solutions are utilized in over 300 institutions across 13 countries, demonstrating its commitment to advancing radiological practices and supporting medical professionals in prioritizing patient care.

Numa Health is a medical bioinformatics company that develops a digital health platform aimed at helping individuals optimize their health and well-being. The platform offers tools that reinterpret blood test results, providing users with insights into their body's functioning. By delivering accessible health information, Numa Health enables individuals to measure, understand, and take action regarding their health, fostering a greater commitment to personal health management.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

IA Medical transforms raw data into intelligent patient knowledge. Its algorithms help to understand patient data, from diagnosis to follow-up, to support them with its conversational agents but also to set up a hybrid solution of cognitive and behavioral therapies.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Santé Académie is an online training platform focused on providing continuous medical education to healthcare professionals. Recognizing the evolving roles of caregivers and the rapid obsolescence of medical knowledge, the platform offers high-quality educational videos tailored to the schedules of busy professionals. Each course is divided into short episodes ranging from 5 to 15 minutes, allowing doctors, nurses, pharmacists, and care assistants to learn at their own pace. The courses cover clinical and regulatory topics and are certified by the ANDPC, produced by experts from prestigious institutions. With the aim of enhancing patient care and engagement, Santé Académie has already gained approval from over 20,000 professionals and health institutions, making advanced medical knowledge accessible directly from mobile devices.

Deemea is a developer of a digital medical assistance platform tailored for clinical research and the analysis of real-life data. The company's AI-driven platform assists clinical research operators by streamlining the imaging data journey, enhancing efficiency and reliability. It utilizes artificial intelligence to identify suitable databases, expedites contractual and regulatory processes, and simplifies external model validation. Additionally, Deemea's platform optimizes responses to internal and external requests while valorizing real-world data and clinical studies. Through these capabilities, Deemea supports clients in accelerating the development and deployment of innovative projects that leverage AI tools specific to the valorization of medical data.

Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Previa Medical is a health technology company that focuses on analyzing patient data in real-time to identify risks of complications and provide predictive insights. Utilizing FHIR technology, the company's platform integrates with existing hospital software, accessing electronic health records (EHR), laboratory results, vital signs, and medical history. This comprehensive data analysis enables healthcare professionals to promptly identify at-risk patients and deliver necessary treatments, ultimately enhancing patient survival rates. Previa Medical's solutions aim to improve the efficiency and effectiveness of healthcare delivery by leveraging advanced data analytics.

Previa Medical is a health technology company that focuses on analyzing patient data in real-time to identify risks of complications and provide predictive insights. Utilizing FHIR technology, the company's platform integrates with existing hospital software, accessing electronic health records (EHR), laboratory results, vital signs, and medical history. This comprehensive data analysis enables healthcare professionals to promptly identify at-risk patients and deliver necessary treatments, ultimately enhancing patient survival rates. Previa Medical's solutions aim to improve the efficiency and effectiveness of healthcare delivery by leveraging advanced data analytics.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Remedee Labs SAS is a French company founded in 2016, specializing in the research and development of a personal endorphin stimulator aimed at pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a device designed to stimulate the release of the body’s own endorphins on demand. This innovative technology is particularly focused on helping individuals suffering from chronic pain conditions, with an initial emphasis on fibromyalgia. Remedee Labs has developed a patient-centered digital service platform that collaborates with medical practitioners to enhance chronic pain management. Backed by a decade of pre-clinical and clinical research, the company aims to provide a new approach to pain relief for the 1.5 billion people worldwide affected by chronic pain, many of whom are dissatisfied with existing treatment options. In 2019, Remedee Labs secured significant funding from various investors to further its mission of making endorphin-stimulation therapy accessible and effective for personal healthcare.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

MOTEN Technologies specializes in muscle sensor technology and an analysis platform designed to prevent musculoskeletal disorders (MSDs) by measuring muscular effort. The company offers a range of services, including data processing, physical assistance, and analysis software. Their solutions enable decision-makers to optimize workstations and tasks for operators by monitoring body motion and associated muscular fatigue. By focusing on these areas, MOTEN Technologies aids companies in reducing the risks of MSDs, thereby promoting employee health and well-being.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

BioMAdvanced Diagnostics focuses on developing molecular diagnostic and biomarker tests that enhance patient care by integrating seamlessly into existing diagnostic and treatment protocols. The company's tests are designed to be user-friendly for healthcare personnel and economically accessible. By providing predictive scores and identifying biomarkers, these tests assist clinicians in evaluating and diagnosing the risk of transplant rejection, thereby enabling more effective and individualized treatment strategies. This approach aims to significantly improve patient outcomes by equipping physicians with advanced tools to monitor and manage their patients' immune responses.

Guerbet is a healthcare company focused on medical imaging, with a history spanning 90 years. As a pioneer in contrast media, it is the only pharmaceutical group dedicated exclusively to this field. Guerbet operates in nearly 80 countries through a network of subsidiaries and distributors, providing a wide array of products for various imaging modalities, including CT scans, magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company’s portfolio includes well-known brands such as Xenetix, Optiray, Dotarem, and Telebrix, among others. Additionally, Guerbet offers injectors and related medical devices aimed at enhancing patient diagnosis, prognosis, and overall quality of life.

Incepto Medical SAS, established in 2018 and headquartered in Paris, France, specializes in developing and distributing artificial intelligence (AI) applications for medical imaging. The company's portfolio includes software solutions like Qure.ai qER for head CT analysis, Qure.ai qXR for thorax abnormality detection, Aidence Veye Chest for pulmonary nodule tracking, Icometric Icobrain for neurological disorder monitoring, and ScreenPoint Transpara for breast cancer detection. Additionally, Incepto operates Collective Minds Radiology, an online platform facilitating case support, opinion sharing, and learning among healthcare professionals. The company aims to empower healthcare professionals by providing AI-driven tools that help manage the increasing volume of patients and images, ultimately enhancing patient care.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Carroucell specializes in providing microcarriers for cell culture in bioreactors. The company has developed a unique microscopic matrices platform that features flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing processes by addressing common performance challenges associated with traditional cell culture methods. Carroucell's products are tailored to meet the needs of customers in the biopharmaceutical industry, facilitating improved outcomes in cell culture applications.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in the resolution of inflammation, utilizing monoclonal antibodies to address these conditions. By inhibiting specific targets implicated in early inflammatory processes and the recruitment of innate immune cells, Thabor Therapeutics aims to provide effective therapies that enable healthcare providers to improve patient outcomes.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Ludocare focuses on developing therapeutic robots that assist patients with chronic diseases and their families. The company's innovative devices are designed to complement traditional drug treatments by providing personalized support that enhances treatment efficiency. By empowering patients, especially children, Ludocare aims to improve therapeutic compliance both quantitatively and qualitatively. This approach facilitates better disease management and helps stabilize essential treatments, ultimately contributing to improved autonomy and quality of life for patients and their families.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Nurea develops a decision-making support solution specifically for healthcare professionals, particularly vascular surgeons. The company specializes in medical imaging software that automates image analysis, providing accurate quantitative assessments to aid in the diagnosis of vascular diseases. Its platform facilitates the management of patient groups during both pre- and post-operative monitoring through an automated workflow, which includes comprehensive full-body scan analysis. By offering decision indicators aimed at preventing cardiovascular incidents, Nurea simplifies the decision-making process for surgeons, enhancing patient care in the realm of cardiovascular health. An online inquiry form is available on their website for further information.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

Intradys is a developer of medical software technologies focused on interventional neuroradiology. The company creates algorithms that leverage machine learning and mixed reality to assist practitioners in formulating optimal strategies based on various criteria, including patient age, medical history, and the suitability of devices for specific conditions. By utilizing imaging obtained before or during procedures, Intradys enables neuroradiologists to make informed decisions in real-time during surgeries, thereby enhancing the overall effectiveness of interventional treatments.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.

Diabeloop is a medical device company based in Grenoble, France, focused on innovating diabetes treatment through advanced technology. Founded in 2015, the company specializes in developing an AI-based closed-loop system that automates insulin delivery for individuals with type 1 diabetes. This system includes a blood sugar monitoring device that combines a glucose sensor, an insulin pump, and a smartphone application featuring an embedded algorithm. By continuously measuring glucose levels and delivering the appropriate insulin dosage, Diabeloop aims to reduce the mental burden on patients, allowing them to manage their condition more effectively and live their lives with greater ease.

Implicity is a developer of a remote monitoring platform that specializes in the smart monitoring of patients with connected cardiac devices, such as pacemakers and defibrillators. The platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on individual medical contexts. This capability allows cardiologists and healthcare professionals to automate the monitoring process, enabling them to effectively oversee patient health while consolidating information on a single platform. By streamlining remote monitoring, Implicity aims to enhance the quality of care provided to patients with cardiac implants.

Mobee Travel is a vacation booking platform specifically designed for individuals with reduced mobility. It offers over 30,000 accessible accommodations worldwide, each verified to ensure they meet the specific needs of travelers with disabilities. The platform not only facilitates the booking of verified hotels but also provides essential medical equipment on-site, ensuring that travelers have everything they require for a comfortable stay. By focusing on the unique needs of its customers, Mobee Travel simplifies the process of planning and booking accessible travel and tourism experiences.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Vaxxel is a biotechnology company focused on developing innovative live-attenuated vaccines targeting critical respiratory diseases, specifically bronchiolitis and pneumonia caused by pneumoviruses. The company specializes in creating novel vaccine candidates aimed at treating infections associated with human metapneumovirus and the human respiratory virus. By leveraging its proprietary platform, Vaxxel aims to provide effective solutions for healthcare providers to combat these significant health challenges.

Brenus Pharma is focused on developing cell-based immunotherapies aimed at treating solid tumors. The company utilizes an allogeneic platform to create anti-cancer cell vaccines, which leverage the patient's immune system to combat cancer and reduce the risk of treatment resistance. Their approach emphasizes generating multiple candidate therapies efficiently, allowing for cost-effective scaling and integration with existing treatment standards. With a strong intellectual property portfolio and a team of experienced professionals, including renowned oncologists, Brenus Pharma seeks to educate the immune system to recognize and respond to tumor-associated and tumor-specific antigens, enhancing the effectiveness of chemotherapy and radiotherapy in cancer care.

Archeon is focused on creating innovative solutions for the monitoring, diagnosis, and treatment of critically ill patients in prehospital care. The company develops artificial intelligence-based technologies aimed at enhancing ventilation quality in emergency medical services. Its products are designed to be practical, user-friendly, and intuitive for emergency caregivers, providing real-time feedback on the quality of ventilation administered to patients. This approach aims to improve patient outcomes and support medical professionals in high-pressure situations.

Doctolib is an online healthcare booking platform and management software provider based in Paris, France, founded in 2013. The company offers a comprehensive service for healthcare practitioners, enabling them to manage appointments, reduce no-shows, and attract new patients. For patients, Doctolib provides a free and user-friendly online service that allows individuals to easily find local health practitioners and book appointments for medical or dental consultations at any time. By streamlining the appointment process, Doctolib enhances access to healthcare services for both professionals and patients, facilitating better management of consultations and patient interactions.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.

Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.

Cell-Easy SAS is a contract development and manufacturing organization based in Toulouse, France, specializing in stem cell services for preclinical and clinical drug development. Founded in 2017, the company focuses on providing ready-to-inject adipose-derived allogeneic stem cells, utilizing biological material from healthy donors. This approach enables the healthcare industry to reduce manufacturing costs associated with stem cell therapies, addressing affordability challenges in the field. By streamlining access to these stem cells, Cell-Easy supports various development projects aimed at improving patient outcomes.

NaoX Technologies is focused on preventing neurological disorders through innovative connected solutions. The company has developed wireless headphones equipped with integrated sensors that passively monitor brain activity by detecting brain vibrations. These headphones record electroencephalogram data in real time and aggregate the information on a software dashboard for healthcare professionals. By providing this technology, NaoX Technologies aims to democratize access to neurological disorder prevention and support patients in their recovery from mental health issues.

Cureety is a telemedicine startup focused on enhancing the follow-up and care of cancer patients through its healthcare telemonitoring platform. The platform provides tools that support healthcare professionals in adjusting cancer treatments and collecting real-world data. This data collection not only aids in better patient care but also contributes to research initiatives, allowing researchers and industry stakeholders to advance their understanding and treatment of cancer. By transforming the care pathway for cancer patients, Cureety aims to improve overall patient outcomes and foster ongoing research programs in the field.

Starkage Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients suffering from various health conditions. The company is developing a platform that targets the depletion of senescent cells, which are linked to age-related diseases, through a combination of immunotherapy and cancer treatment approaches. Starkage Therapeutics aims to address unmet medical needs in areas such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibrosis. Through its innovative research and therapeutic strategies, the company seeks to enhance patient health and treatment outcomes.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

Diaccurate is a biotechnology company based in Paris, France, that focuses on researching and developing treatments for various diseases, including HIV infection and several types of cancer. Founded in 2012, the company targets conditions such as endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring innovative therapeutic approaches in oncology, aiming to provide effective solutions for patients facing these challenging and often incurable diseases.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.